

Dear FEMSelect Investors,

We hope everyone is well. We are excited about our progress and we realize we are overdue for an update on 2023.

As you know, FEMSelect Ltd. has been dedicated to transforming the treatment of prolapse for both women and urogynecology through our minimally invasive technology, EnPlace®. With your continued support and confidence in our vision, we have achieved significant milestones, over 3,000 women treated to date, over 100 US hospitals with Value Analysis (VAC) approval 40% growth in YOY sales.

2023, however, was not without challenges including the War in Israel (all our employees are safe, business operations are unaffected) and a transition away from our selling partner LiNA (Nov 2023) which have led to a cash crunch. Challenges continue but nothing we cannot overcome as we have multiple options in motion.

To continue to grow from here, we are seeking additional investment in the form of a convertible note to fuel significant commercialization growth and provide working capital to bridge to break-even while continuing efforts to align with effective Strategic Partners. The collateralized convertible note we are offering presents a unique investment proposition, combining the security of collateral with the potential upside of conversion into equity.

Here are some key highlights of the collateralized convertible note opportunity:

1. **Security**: Your investment will be backed by collateral, providing an added layer of protection for your capital.
2. **Convertible**: The note is convertible into equity at a predetermined conversion ratio, allowing you to potentially participate in the future success of FEMSelect Ltd.
3. **Attractive Returns**: With recent interest in Femtech as witnessed by Boston Scientific's acquisition of Axonics \$3.7B and the trajectory of our growth to reach run rate of \$20-30M by 2027, we believe that investing in FEMSelect Ltd. presents an opportunity for attractive returns on your investment.

I invite you to review the accompanying materials, which provide detailed information regarding the terms of the collateralized convertible note. **We will be hosting a Zoom call for all investors on Monday, March 25<sup>th</sup> at 9:00amEST to review FEMSelect's progress to date and this investment opportunity.** A Zoom invitation will be sent shortly and the call will be recorded for those who are unable to attend. Should you have any questions or require additional information, please do not hesitate to reach out to me directly.

Thank you for your ongoing support and belief in the potential of FEMSelect Ltd. We value our partnership with you and look forward to continuing this journey together.

Regards,  
Debbie

Debbie Garner

Co-CEO

FEMSelect Ltd.

Tel US: +1-215-940-8178

Tel Israel: +972-54-945-6260

Email: [debbie@femselect.com](mailto:debbie@femselect.com)

[FEMSelect - 2024 Convertible Note Financing Term Sheet 05b MMW 20.3.24](#)

[2024 03 20 FEMSelect 1 Page Overview](#)

[Zoom Recording of the Investor Call](#)